Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Fish and Richardson
QuintilesIMS
Dow
Chubb
Deloitte
Johnson and Johnson
US Army
Mallinckrodt
Citi

Generated: December 12, 2018

DrugPatentWatch Database Preview

Litigation Details for Sanofi-Aventis v. Apotex Inc. (D. Del. 2008)

« Back to Dashboard

Small Molecule Drugs cited in Sanofi-Aventis v. Apotex Inc.
The small molecule drug covered by the patents cited in this case is ➤ Sign Up .

Details for Sanofi-Aventis v. Apotex Inc. (D. Del. 2008)

Date Filed Document No. Description Snippet Link To Document
2008-06-23 107 Case Transferred In - District Transfer States Patent No. 4,661,491 (“the ‘491 patent”) (Exhibit A). This action is based upon the Patent Laws…United States Patent No. 4,661,491 (“the ’491 patent”) and that a copy of the ’491 patent appears to…States Patent No. 4,661,491 (“the ‘491 patent”) (Exhibit A). This action is based upon the Patent Laws…United States Patent No. 4,661,491 (“the ’491 patent”) and that a copy of the ’491 patent appears to…Office (“PTO”) issued U.S. Patent No. 4,661,491 (“the ’491 patent”), entitled “AFLUZOSINE COMPOSITIONS External link to document
2008-06-23 108 Remark United States Patent No. 4,661,491 ("the '491 patent"), a patent assigned to Plaintiff…for the infringement of U.S. Patent No. 4,661,491 (“the ‘491 patent”), listed in the FDA’s Approved…assignee of United States Patent No. 4,661,491 ("the '491 patent"), titled "Alfuzosine… assignee of United States Patent No. 4,661,491 ("the '491 patent"), titled "…judgments that U.S. Patent No. 6,149,940 (“the ‘940 patent”), a second patent listed in the Orange Book External link to document
2008-06-23 109 Remark of United States Patent No. 4,661,491 ("the '491 patent"), a patent assigned to Plaintiff…of United States Patent No. 4,661,491 ("the '491 patent"), a patent assigned to Plaintiff…assignee of United States Patent No. 4,661,491 ("the '491 patent"), titled "Alfuzosine…infringement of United States Patent No. 4,661,491 ("the '491 patent") by filing an Abbreviated…the '491 patent and/or United States Patent No. 6,149,940 ("the '940 patent"), another External link to document
2008-06-23 110 Remark (s) 4,661,491; 6,149,940; (ead) (Entered: 09/24/2007) 09/25/2007 5 Return…regarding the patents at issue, the patent applications for the patents at issue…Defendant Cause: 35:0271 Patent Infringement Nature of Suit: 830 Patent …4 Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number … inventions of both the patent asserted by sanofi-aventis and the patent in Apotex’s counterclaims External link to document
2008-06-23 111 Remark respect to U.S. Patent Nos. 4,661,491 (the ‘491 patent) and 6,149,940 (the ‘940 patent), which are both…respect to U.S. Patent Nos. 4,661,491 (the ‘491 patent) and 6,149,940 (the ‘940 patent), which are both…Defendant Cause: 35:0271 Patent Infringement Nature of Suit: 830 Patent …LITIGATION IN RE: ALFUZOSIN HYDROCHLORIDE PATENT LITIGATION …Administration’s register of pharmaceutical patents for sanofi’s Uroxatral drug. Centralization under External link to document
2008-06-23 113 Answer to Complaint States Patent No. 4,661,491 (“the ‘491 patent”) (Exhibit A). This action is based upon the Patent Laws…United States Patent No. 4,661,491 (“the ’491 patent”) and that a copy of the ’491 patent appears to…Office (“PTO”) issued U.S. Patent No. 4,661,491 (“the ’491 patent”), entitled “AFLUZOSINE COMPOSITIONS… The ‘491 Patent 11. On April 28, 1987, the ‘491 patent, titled “Alfuzosine…admit that the ’491 patent issued on April 28, 1987, but deny that this patent was duly and legally External link to document
Date Filed Document No. Description Snippet Link To Document

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Colorcon
McKesson
Express Scripts
Cipla
US Army
Boehringer Ingelheim
Julphar
Cantor Fitzgerald
Citi

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.